Treatment of pulmonary hemangiomatosis with recombinant interferon alfa-2a.

A subsea pipeline hub is connected to the hub of an adjacent spool piece connected to an in-place manifold of a subsea structure used in the production of oil and/or gas. The pipeline hub is positioned relative to the opposing spool hub and a remotely operated pipeline connecting tool is lowered from the water's surface to the subsea structure using guidelines and structural guidance for alignment of the pipeline hub with the spool piece hub. The spool piece hub is then drawn to the pipeline hub and the hubs are clamped together by operation of the connecting tool. The seal in the connection can be tested by means of the connecting tool. The spool piece may be retrieved and replaced by the connecting tool if maintenance is needed. Connecting tool operations are powered by hydraulic fluid and controlled from the surface. The pipeline hub may be lowered vertically and pivoted into its position adjacent the spool piece or may be pulled into that position.

[1]  N. Kaiser,et al.  The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells. , 1985, Experimental cell research.

[2]  Z. Fuks,et al.  Interferon enhances prostacyclin production by cultured vascular endothelial cells. , 1984, The Journal of clinical investigation.

[3]  J. Thompson,et al.  Diffuse pulmonary hemangiomatosis. , 1978, Radiology.

[4]  Fredy Alexander,et al.  Diffuse neonatal hemangiomatosis. , 1970, Pediatrics.

[5]  P. Koblenzer,et al.  Angiomatosis (hamartomatous hem-lymphangiomatosis). Report of a case with diffuse involvement. , 1961, Pediatrics.

[6]  F. Real,et al.  Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Spijker,et al.  Capillary haemangiomatosis of the lungs , 1978, Histopathology.

[8]  E. Mark,et al.  Thoracic hemangiomatosis masquerading as interstitial lung disease. , 1988, Chest.

[9]  E. Maeyer,et al.  IMMUNOREGULATORY ACTION OF TYPE I INTERFERON IN THE MOUSE * , 1980 .

[10]  H. Ichinose,et al.  Pulmonary veno-occlusive disease: Report of a case with pseudoangiomatous features , 1977 .

[11]  C. Pickering,et al.  Pulmonary capillary haemangiomatosis. , 1983, Diagnostic histopathology.

[12]  J. Reuben,et al.  Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Zetter,et al.  Inhibition of cell motility by interferon. , 1980, Science.

[14]  R. Kurzrock,et al.  Clinical toxicity of interferons in cancer patients: a review. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Merigan.  Human interferon as a therapeutic agent: a decade passes. , 1988, The New England journal of medicine.

[16]  P. Volberding,et al.  Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.

[17]  J. Hoofnagle,et al.  Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. , 1985, Laboratory investigation; a journal of technical methods and pathology.

[18]  E. Wang,et al.  Interferon effects on microfilament organization cellular fibronectin distribution, and cell motility in human fibroblasts , 1980, The Journal of cell biology.

[19]  D. Ingber,et al.  Inhibition of angiogenesis through modulation of collagen metabolism. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[20]  A. Churg,et al.  Pulmonary capillary hemangiomatosis. , 1985, The American review of respiratory disease.

[21]  J. Rouleau,et al.  Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. , 1988, Annals of internal medicine.

[22]  R. Friesel,et al.  Inhibition of endothelial cell proliferation by gamma-interferon , 1987, The Journal of cell biology.

[23]  P. Grimley,et al.  Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2',5' oligoadenylate synthetase induction. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[24]  Randall,et al.  Gamma-interferon inhibits collagen synthesis in vivo in the mouse. , 1987, The Journal of clinical investigation.